Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-26T07:55:57.308Z Has data issue: false hasContentIssue false
  • English
  • Français

The New Era of Comparative Effectiveness: Will Public Health End up Left Behind?

Published online by Cambridge University Press:  01 January 2021

Richard S. Saver
Get access Rights & Permissions [Opens in a new window]

Extract

As a result of health care reform, medicine has entered a new era of comparative effectiveness. The Patient Protection and Affordable Care Act (PPACA) created the nation’s first comprehensive comparative effectiveness research (CER) program, investing in CER at record levels and establishing a new regulatory framework for oversight of the research. CER attracts considerable enthusiasm as a tool for reform because it compares competing interventions to determine which works best, supplying critical information for medical decision-making and health policy. In theory, better evidence of how treatments fare relative to one another will translate to better medical care. According to some optimistic accounts, CER can lead to a “revolution” in clinical practice, has transformative power “to reshape major portions of the practice of medicine,” and represents a major “turning point” for the health care system.

Type
Symposium
Information
Journal of Law, Medicine & Ethics , Volume 39 , Issue 3 , Fall 2011 , pp. 437 - 449
Copyright
Copyright © American Society of Law, Medicine and Ethics 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Patient Protection and Affordable Care Act, Pub. L. No. 111–148, 124 Stat. 119 (2010) (hereinafter cited as PPACA).Google Scholar
Wachter, B., “Are We Mature Enough to Make Use of Comparative Effectiveness Research?” Wachter's World, available at <http://community.the-hospitalist.org/blogs/wachters_world/archive/2009/02/21/are-we-mature-enough-to-make-use-of-comparative-effectiveness-research.aspx> (last visited June 13, 2011). (last visited June 13, 2011).' href=https://scholar.google.com/scholar?q=Wachter,+B.,+“Are+We+Mature+Enough+to+Make+Use+of+Comparative+Effectiveness+Research?”+Wachter's+World,+available+at++(last+visited+June+13,+2011).>Google Scholar
Akhter, M. N. Levinson, R. A., “Comparative Effectiveness Research and the Future Practice of Medicine,” Journal of the National Medical Association 101, no. 12 (2009): 1301–1302, at 1301.CrossRefGoogle Scholar
Dentzer, S., “Comparative Effectiveness: Coherent Health Care at Last?” Health Affairs 29, no. 10 (2010): 1756.CrossRefGoogle Scholar
Teutsch, S. M. Fielding, J. E., “Applying Comparative Effectiveness Research to Public and Population Health Initiatives,” Health Affairs 30, no. 2 (2011): 349–355.CrossRefGoogle Scholar
Saver, R., “Health Care Reform's Wild Card: The Uncertain Effectiveness of Comparative Effectiveness Research,” University of Pennsylvania Law Review 159 (forthcoming 2011); Avorn, J. Fischer, M., “‘Bench to Behavior’: Translating Comparative Effectiveness Research into Improved Clinical Practice,” Health Affairs 29, no. 10 (2010): 1891–1900.Google Scholar
Sox, H. C. Greenfield, S., “Comparative Effectiveness Research: A Report from the Institute of Medicine,” Annals of Internal Medicine 151, no. 3 (2009): 203–205, at 204.CrossRefGoogle Scholar
Federal Coordinating Council for Comparative Effectiveness Research, U.S. Department of Health and Human Services, Report to the President and the Congress (2009), at 17–21 (hereinafter cited as Federal CER Council).Google Scholar
See 21 C.F.R. § 312.21 (2010); O'Connor, A. B., “Building Comparative Efficacy and Tolerability Into the FDA Approval Process,” JAMA 303, no. 10 (2010): 979–980.CrossRefGoogle Scholar
Congressional Research Service, Comparative Clinical Effectiveness and Cost-Effectiveness Research: Background, History, and Overview (2007).Google Scholar
Id., at 5.Google Scholar
See Saver, , supra note 6.Google Scholar
Institute of Medicine, Learning What Works Best: The Nation's Need for Evidence on Comparative Effectiveness in Health Care (Washington, D.C.: The National Academies Press, 2007): At 2 (hereinafter cited as IOM, Learning What Works Best).Google Scholar
See Federal CER Council, supra note 8, at 3; Congressional Budget Office, Research on the Comparative Effectiveness of Medical Treatments: Issues and Options for an Expanded Federal Role (2007): At 12; Fisher, E. S. et al., “Slowing the Growth of Health Care Costs – Lessons from Regional Variation,” New England Journal of Medicine 360, no. 9 (2009): 849–852.CrossRefGoogle Scholar
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 provided about $15 million per year to AHRQ for research into outcomes and comparative clinical effectiveness of certain items and services. Pub. L. No. 108–173, § 1013(e), 117 Stat. 2066 (2003).Google Scholar
Institute of Medicine, Initial National Priorities for Comparative Effectiveness Research (Washington, D.C.: National Academies Press, 2009): At 43–51 (hereinafter cited as IOM, Initial National Priorities); see Federal CER Council, supra note 8, at 12–13.Google Scholar
American Recovery and Reinvestment Act, Pub. L. No. 111–5, 123 Stat. 115 (2009).Google Scholar
Id. § 804.Google Scholar
Id. tit. VIII.Google Scholar
See IOM, Initial National Priorities, supra note 16.Google Scholar
See PPACA, supra note 1, §6301(a).Google Scholar
Id. § 6301(a).Google Scholar
Id. § 6301(e); Nussbaum, A. et al., “Obamacare's Cost Scalpel,” Business Week, April 5, 2010, at 64.Google Scholar
See Will, G. F., “Stimulus Math for the GOP,” Washington Post, January 29, 2009, at A19; McCaughey, B., Ruin Your Health with the Obama Stimulus Plan, February 9, 2009, available at <http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aLzfDxfbwhzs>(last visited June 13, 2011);; Colliver, V., “Stimulus Prompts Talk of Health Care Rationing,” San Francisco Chronicle, February 12, 2009, at A12.(last+visited+June+13,+2011);;+Colliver,+V.,+“Stimulus+Prompts+Talk+of+Health+Care+Rationing,”+San+Francisco+Chronicle,+February+12,+2009,+at+A12.>Google Scholar
See PPACA, supra note 1, §6301(c).Google Scholar
Id. § 6301(c).Google Scholar
Id.Google Scholar
Id.Google Scholar
Id.Google Scholar
See Teutsch, Fielding, , supra note 5, at 350.Google Scholar
Perencevich, E. N. Lautenbach, E., “Infection Prevention and Comparative Effectiveness Research,” JAMA 305, no. 14 (2011): 1482–1483, at 1482.CrossRefGoogle Scholar
See Federal CER Council, supra note 8, at 3.Google Scholar
Gostin, L. O. et al., “Restoring Health to Health Reform: Integrating Medicine and Public Health to Advance the Population's Wellbeing,” University of Pennsylvania Law Review 159 (forthcoming 2011).Google Scholar
See Teutsch, Fielding, , supra note 5, at 349.Google Scholar
Volpp, K. G. Das, A., “Comparative Effectiveness – Thinking beyond Medication A Versus Medication B,” New England Journal of Medicine 361, no. 4 (2009): 331–333, at 331. See also Hochman, M. McCormick, D., “Characteristics of Published Comparative Effectiveness Studies of Medications,” JAMA 303, no. 10 (2010): 9–958.CrossRefGoogle Scholar
See, e.g., 210 ILL. COMP. STAT. ANN. 83/5 (West 2011); TENN. CODE ANN. § 68-11-269 (West 2011).Google Scholar
See Perencevich, Lautenbach, , supra note 31, at 1482.Google Scholar
See Givhan, R., “First Lady Michelle Obama: “Let's Move’ and Work on Childhood Obesity Problem,” Washington Post, February 10, 2010.Google Scholar
Kindig, D. Mullahy, J., “Comparative Effectiveness – of What?: Evaluating Strategies to Improve Population Health,” JAMA 304, no. 8 (2010): 901–902. See also Ness, R. et al., “The Future of Epidemiology,” Academic Medicine 84, no. 11 (2009): 1631–1637, at 1634–1635 (“Scientists and physicians know remarkably little about the antecedents to childhood overweight and obesity…. Intervention studies…must be tested.”).CrossRefGoogle Scholar
See “Influenza Vaccine Payment Allowances-Annual Update for 2010–2011 Season,” Medicare B Update: A Newsletter for MAC Jurisdiction 9 Providers, December, 2010, at 12, available at <http://medicare.fcso.com/publications_B/186385.pdf> (last visited June 13, 2011); (guidance from a regional Medicare carrier to Medicare providers); “Fluzone High-Dose Vaccine Covered Under Medicare Part B,” Drug Topics, July 20, 2010, available at <http://drugtopics.modernmedicine.com/drugtopics/Clinical+News/Fluzone-High-Dose-vaccine-covered-under-Medicare-P/Article/detail/679710> (last visited June 13, 2011).+(last+visited+June+13,+2011);+(guidance+from+a+regional+Medicare+carrier+to+Medicare+providers);+“Fluzone+High-Dose+Vaccine+Covered+Under+Medicare+Part+B,”+Drug+Topics,+July+20,+2010,+available+at++(last+visited+June+13,+2011).>Google Scholar
Falsey, A. R. et al., “Randomized, Double-Blind Controlled Phase 3 Trial Comparing the Immunogenicity of High-Dose and Standard-Dose Influenza Vaccine in Adults 65 Years of Age and Older,” Journal of Infectious Diseases 200, no. 2 (2009): 172–180.CrossRefGoogle Scholar
Crawford, G. B., “Continued Debate on Comparative Effectiveness Research,” Health Affairs 29, no. 12 (2010): 2353.CrossRefGoogle Scholar
Smith, S. et al., “Comparative Effectiveness of Five Smoking Cessation Pharmacotherapies in Primary Care Clinics,” Archives of Internal Medicine 169, no. 22 (2009): 2148–2155.CrossRefGoogle Scholar
Diabetes Prevention Program Research Group, “Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin,” New England Journal of Medicine 346, no. 6 (2002): 393–403.CrossRefGoogle Scholar
An, L. C. et al., “The Comparative Effectiveness of Clinic, Work-Site, Phone, and Web-Based Tobacco Treatment Programs,” Nicotine and Tobacco Research 12, no. 10 (2010): 989–996.CrossRefGoogle Scholar
See Federal CER Council, supra note 8, at 10.Google Scholar
Symposium authors Sharona Hoffman and Andy Podgurski explore this interesting potential for CER in their intriguing discussion of how CER might be effectively used with electronic health records. They consider how integration of CER with electronic health records can enable, at the time of medical decision-making, more personalized comparisons of treatment effectiveness for different patient groups. See Hoffman, S. Podgurski, A., “Improving Health Care Outcomes through Personalized Comparisons of Treatment Effectiveness Based on Electronic Health Records,” Journal of Law, Medicine & Ethics 39, no. 3 (2011): 425–436.CrossRefGoogle Scholar
See Gostin, , supra note 33.Google Scholar
Gostin, L. O., Public Health Law: Power, Duty, Restraint, 2nd. ed. (Berkeley: University of California Press, 2008): At 493.Google Scholar
Id.Google Scholar
See PPACA, supra note 1, § 6301(a).Google Scholar
See Kindig, Mullahy, , supra note 39, at 901.Google Scholar
See PPACA, supra note 1, § 6301(a) (emphasis added).Google Scholar
Id.Google Scholar
Id. (emphasis added).Google Scholar
See Teutsch, Fielding, , supra note 5, at 353.Google Scholar
Thorpe, J. H., “Comparative Effectiveness Research and Health Reform: Implications for Public Health Policy and Practice,” Public Health Reports 125, no. 6 (2010): 909–912, at 910.Google Scholar
See Gostin, , supra note 49, at 17. See also Gostin, L.O., “Health of the People: The Highest Law?” Journal of Law, Medicine & Ethics 32, no. 3 (2004): 509–515, at 510 (“The field of public health would profit from a vibrant conception of ‘the common’ that sees public interests as more than the aggregation of individual interests.”).CrossRefGoogle Scholar
See IOM, supra note 16, at 34–36 and table 2.1 (providing a comprehensive list of varying definitions of CER adopted by public and private entities in recent years).Google Scholar
Id., at 13 (emphasis added).Google Scholar
See Thorpe, , supra note 57, at 909.Google Scholar
See Kindig and Mullahy, supra note 39, at 902.Google Scholar
See IOM Initial National Priorities, supra note 16.Google Scholar
For example, the IOM Report's first quartile of high priority CER topics includes a recommendation to study the comparative effectiveness of various screening, prophylaxis, and treatment interventions in eradicating MRSA in communities, institutions, and hospitals. Id., at 107.Google Scholar
Kaats, G. R. et al., “Comparative Effectiveness Research (CER): Opportunities and Challenges for the Nutritional Industry,” Journal of the American College of Nutrition 28, no. 3 (2009): 234–237.CrossRefGoogle Scholar
U.S. Government Accountability Office, GAO Announces Appointments to New Patient-Centered Outcomes Research Institute Board of Governors, Press Release, September 23, 2010, available at <http://www.gao.gov/press/pcori2010sep23.html> (hereinafter cited as GAO Press Release) (last visited June 13, 2011).+(hereinafter+cited+as+GAO+Press+Release)+(last+visited+June+13,+2011).>Google Scholar
The initial chair of the PCOR Institute's Board of Governors, UCLA Medical School Dean Eugene Washington, earlier in his career worked for the Centers for Disease Control and Prevention in the U.S. Public Health Service and a few other members of the initial governing board have public health training to some degree. But most members of the initial board do not have extensive public health backgrounds. See Id.Google Scholar
The statute requires that members on the governing board include physicians and other health care provider representatives. It also requires that the provider members include a surgeon, nurse, integrative health care practitioner, and hospital representative. PPACA further provides that the governing board should collectively have expertise in clinical health sciences research, including, among other topics, epidemiology. But the statute does not otherwise specify how many board members must have epidemiology expertise. It also does not otherwise require that board members have extensive specialty training in public health (or in any other area for that matter) or come from particular public health practice backgrounds. See PPACA, supra note 1, § 6301(a).Google Scholar
See Fieldstein, M., “ObamaCare Is All About Rationing,” Wall Street Journal, August 19, 2009, at A15.Google Scholar
See PPACA, supra note 1, § 6301(a).Google Scholar
See Gostin, et al., supra note 33.Google Scholar
Luce, B. R. et al., “Rethinking Randomized Clinical Trials for Comparative Effectiveness Research: The Need for Transformational Change,” Annals of Internal Medicine 151, no. 3 (2009): 206–209.CrossRefGoogle Scholar
Id. Sullivan, P. Goldmann, D., “The Promise of Comparative Effectiveness Research,” JAMA 305, no. 4 (2011): 400–401.CrossRefGoogle Scholar
See Perencevich and Lautenbach, supra note 31, at 1482–1483 Tunis, S. R. et al., “Practical Clinical Trials: Increasing the Value of Clinical Research for Decision Making in Clinical and Health Policy,” JAMA 290, no. 12 (2003): 1624–1632.CrossRefGoogle Scholar
Rich, E. C., “The Policy Debate over Public Investment in Comparative Effectiveness Research,” Journal of General Internal Medicine 24, no. 6 (2009): 752–757.CrossRefGoogle Scholar
See Kaats, et al., supra note 65, at 236.Google Scholar
See Perencevich and Lautenbach, supra note 31, at 1482.Google Scholar
See Teutsch and Fielding, supra note 5, at 351.Google Scholar
See Gostin, et al., supra note 33; Teutsch and Fielding, supra note 5, at 352.Google Scholar
See Teutsch and Fielding, supra note 5, at 351.Google Scholar
See PPACA, supra note 1, § 6301(c).Google Scholar
See Teutsch and Fielding, supra note 5, at 353.Google Scholar
The House reform bill also would have established an independent CER Commission to oversee the activities of the CER program within the AHRQ. Affordable Health Care for America Act, H.R. 3962, 111th Cong. § 1401 (2009).Google Scholar
See PPACA, supra note 1, § 6301(a).Google Scholar
See GAO Press Release, supra note 66.Google Scholar
See, e.g., Lobel, O., “The Renew Deal: The Fall of Regulation and the Rise of Governance in Contemporary Legal Thought,” Minnesota Law Review 89 (2004): 342–470; Hunter, N. D., “‘Public-Private’ Health Law: Multiple Directions in Public Health,” Journal of Health Care Law and Policy 10, no. 1 (2007): 89–119.Google Scholar
Selker, H. P. Wood, A. J. J., “Industry Influence on Comparative-Effectiveness Research Funded through Health Care Reform,” New England Journal of Medicine 361, no. 27 (2009): 2595–2597, at 2596.CrossRefGoogle Scholar
Rothstein, M. A., “Rethinking the Meaning of Public Health,” Journal of Law, Medicine & Ethics 30, no. 2 (2002): 144–149.CrossRefGoogle Scholar
See Gostin, , supra note 49, at 8–9.Google Scholar
See Gostin, , supra note 33.Google Scholar
Patel, K., “Health Reform's Tortuous Route to the Patient-Centered Outcomes Research Institute,” Health Affairs 29, no. 10 (2010): 1777–1782, at 1781.CrossRefGoogle Scholar
See Gostin, , supra note 33.Google Scholar
See generally Elhauge, E., ed., The Fragmentation of U.S. Health Care: Causes and Solutions (New York: Oxford University Press, 2010).CrossRefGoogle Scholar
Glasgow, R. E. et al., “If Diabetes Is a Public Health Problem, Why Not Treat It as One? A Population-Based Approach to Chronic Illness,” Annals of Behavioral Medicine 21, no. 2 (1999): 159–170.CrossRefGoogle Scholar
See Gostin, et al., supra note 33.Google Scholar
Hemenway, D., “Why We Don't Spend Enough on Public Health,” New England Journal of Medicine 362, no. 18 (2010): 1657–1658, at 1657.CrossRefGoogle Scholar
Schulman, D. I. et al., “Public Health Legal Services: A New Vision,” Georgetown Journal on Poverty Law and Policy 15, no. 3 (2008): 729–779; see Gostin, , supra note 33.Google Scholar
See Saver, R., “In Tepid Defense of Population Health: Physicians and Antibiotic Resistance,” American Journal of Law and Medicine 34, no. 4 (2008): 431–491, at 454–461; Sage, W. M., “Relational Duties, Regulatory Duties, and the Widening Gap between Individual Health Law and Collective Health Policy,” Georgetown Law Journal 96, no. 2 (2008): 497–522.CrossRefGoogle Scholar
Rodwin, M. A., “The Politics of Evidence-Based Medicine,” Journal of Health Politics, Policy, and Law 26, no. 2 (2001): 439–446.CrossRefGoogle Scholar
See Saver, , supra note 6.Google Scholar
Id.Google Scholar
Indeed, according to the Federal CER Council, “The purpose of [CER] is to provide information that helps clinicians and patients choose which option best fits an individual patient's needs and preferences.” See Federal CER Council Report, supra note 8, at 3.Google Scholar
See Teutsch and Fielding, supra note 5, at 350.Google Scholar
Indeed, Mark Miller, Executive Director of the Medicare Payment Advisory Commission, expressed his disappointment with the IOM's initial priority list because as part of the CER program's research agenda “we expected to see a lot more drug-drug, device-device medical treatment versus surgical” comparisons than some of the broader health systems questions recommended by the IOM. Miller, M., Remarks at the Public Meeting of the Medicare Payment Advisory Commission 107 (September 17, 2009), available at <http://www.medpac.gov/transcripts/0909MedPAC.pdf> (last visited June 13, 2011) (hereinafter cited as MedPAC Meeting Remarks). (last visited June 13, 2011) (hereinafter cited as MedPAC Meeting Remarks).' href=https://scholar.google.com/scholar?q=Indeed,+Mark+Miller,+Executive+Director+of+the+Medicare+Payment+Advisory+Commission,+expressed+his+disappointment+with+the+IOM's+initial+priority+list+because+as+part+of+the+CER+program's+research+agenda+“we+expected+to+see+a+lot+more+drug-drug,+device-device+medical+treatment+versus+surgical”+comparisons+than+some+of+the+broader+health+systems+questions+recommended+by+the+IOM.+Miller,+M.,+Remarks+at+the+Public+Meeting+of+the+Medicare+Payment+Advisory+Commission+107+(September+17,+2009),+available+at++(last+visited+June+13,+2011)+(hereinafter+cited+as+MedPAC+Meeting+Remarks).>Google Scholar
42 U.S.C. § 1395y(a)(1)(A)-(B) (2006).Google Scholar
See Pearson, S., “From Better Evidence to Better Care: Using Comparative Effectiveness Research to Guide Practice and Policy,” in Brookings Institution, Implementing Comparative Effectiveness Research: Priorities, Methods, and Impact (Washington, D.C.: Engelberg Center for Health Care Reform at Brookings, 2009): At 55–77.Google Scholar
See supra notes 25 to 29 and accompanying text.Google Scholar
See PPACA, supra note 1, §§ 6301(a) and (b).Google Scholar
Id. § 3023.Google Scholar
Id. § 3021(a).Google Scholar
See Saver, , supra note 6.Google Scholar
See Sokolovsky, J., MedPAC Meeting Remarks, supra note 104, at 103.Google Scholar
Merenstein, D., “Winners and Losers,” JAMA 291, no. 1 (2004): 15–16.Google Scholar
Pont, E. A., “The Culture of Physician Autonomy: 1900 to the Present,” Cambridge Quarterly Healthcare Ethics 9, no. 1 (2000): 98–113. See generally Freidson, E., Profession of Medicine: A Study of the Sociology of Applied Knowledge (Chicago: University of Chicago Press, 1972).CrossRefGoogle Scholar
Reinertsen, See J. L., “Zen and the Art of Physician Autonomy Maintenance,” Annals of Internal Medicine 138, no. 12 (2003): 992–995.CrossRefGoogle Scholar
Sokolovsky, J., MedPAC Meeting Remarks, supra note 104, at 100–101.Google Scholar
Mushlin, A. I. Ghomrawi, H., “Health Care Reform and the Need for Comparative-Effectiveness Research,” New England Journal of Medicine 362 (2010): E6(1)-e(6)(3), at e(6) (1), available at <http://www.nejm.org/doi/full/10.1056/NEJMp0912651> (last visited June 23, 2011).CrossRefGoogle Scholar
See Saver, , supra note 98; St. Lawrence, J. S. et al., “STD Screening, Testing, Case Reporting, and Clinical and Partner Notification Practices: A National Survey of U.S. Physicians,” American Journal of Public Health 92, no. 11 (2002): 1784–1788.Google Scholar
Carman, K. L. et al., “Evidence That Consumers Are Skeptical about Evidence-Based Health Care,” Health Affairs 29, no. 7 (2010): 1400–1406.CrossRefGoogle Scholar
Kravitz, R., “Beyond Gatekeeping: Enlisting Patients as Agents for Quality and Cost-Containment,” Journal of General Internal Medicine 23, no. 10 (2008): 1722–1723.CrossRefGoogle Scholar